logo

For the Inventor, By the Inventor

L'Aquila, Italy

Andrea Aramini

USPTO Granted Patents = 22 

 

 

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 22(Granted Patents)


Location History:

  • L'Aquila AQ, IT (2012)
  • L'Aquila, IT (2010 - 2022)

Company Filing History:

goldMedal13 out of 49 
 
Dompe' Farmaceutici S.p.a.
 patents
silverMedal6 out of 14 
 
Dompe Pha.r.ma S.p.a.
 patents
bronzeMedal3 out of 22 
 
Dompe S.p.a.
 patents

Years Active: 2010-2025

Loading Chart...
Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents
1. 12365644 - Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use (2025-07-22),
2. 12358950 - IL-17A binding peptides and medical uses thereof (2025-07-15),
3. 12285396 - Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof (2025-04-29),
4. 12186359 - Composition containing branched-chain amino acids (2025-01-07),
5. 12150933 - IL-8 inihibitors for use in the treatment of some urological disorders (2024-11-26),
6. 12102607 - C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain (2024-10-01),
7. 11236129 - IL-17A binding peptides and medical uses thereof (2022-02-01),
8. 11046662 - 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma (2021-06-29),
9. 10508090 - Sulfonamides as GPR40- and GPR120-agonists (2019-12-17),
10. 10246448 - 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as TRPM8 antagonists (2019-04-02),
11. 10196368 - 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma (2019-02-05),
12. 9856246 - TRPM8 antagonists (2018-01-02),
13. 9585875 - TRPM8 antagonists (2017-03-07),
14. 8906946 - TRPM8 receptor antagonists (2014-12-09),
15. 8624036 - 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them (2014-01-07),

**Title: Andrea Aramini: Innovator in Pharmaceutical Patents from L'Aquila, Italy**

Introduction

Andrea Aramini is an accomplished inventor based in L'Aquila, Italy, whose innovative contributions to the pharmaceutical industry include a significant portfolio of 19 patents. His work focuses on developing advanced therapeutic solutions, particularly in the realm of amino acids and urological disorders.

Latest Patents

Among his latest inventions, one notable patent is for a composition containing branched-chain amino acids (BCAA) combined with the dipeptide L-Alanyl-L-alanine. This invention aims to enhance performance and recovery during physical activity, as well as to prevent or treat muscle wasting associated with various pathological or age-related conditions. Another groundbreaking patent involves IL-8 inhibitor compounds, specifically dual CXCR1/CXCR2 receptor inhibitors. These compounds are designed for the treatment and prevention of interstitial cystitis, painful bladder syndrome, and overactive bladder, including conditions induced by anticancer therapies. Methodologies for treatment, prevention, and kits incorporating these IL-8 inhibitors are also part of this patent.

Career Highlights

Throughout his career, Andrea has worked with esteemed companies such as Dompé Farmaceutici S.p.A. and Dompé Pharma S.p.A. His commitment to innovation in pharmaceuticals has led to substantial advancements in medicine, particularly in enhancing patient care and treatment options.

Collaborations

Andrea has collaborated with notable colleagues in the field, including Gianluca Bianchini and Marcello Allegretti. These partnerships within the pharmaceutical community have fostered an environment of shared knowledge and advancements, contributing to the overall progress in their respective areas of expertise.

Conclusion

With a robust portfolio of patents and a dedication to improving healthcare solutions, Andrea Aramini stands out as a significant figure in the pharmaceutical innovation landscape. His contributions continue to influence the development of effective treatments, addressing complex medical challenges and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…